269 related articles for article (PubMed ID: 24195604)
1. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.
Baldo A; van den Akker E; Bergmans HE; Lim F; Pauwels K
Curr Gene Ther; 2013 Dec; 13(6):385-94. PubMed ID: 24195604
[TBL] [Abstract][Full Text] [Related]
2. Biosafety of viral vectors commonly used in gene therapy and vaccination.
Herman P
Curr Gene Ther; 2013 Dec; 13(6):383-4. PubMed ID: 24397526
[No Abstract] [Full Text] [Related]
3. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.
Goossens M; Pauwels K; Willemarck N; Breyer D
Curr Gene Ther; 2013 Dec; 13(6):413-20. PubMed ID: 24397528
[TBL] [Abstract][Full Text] [Related]
4. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
5. Environmental risk assessment of replication competent viral vectors applied in clinical trials: potential effects of inserted sequences.
van den Akker E; van der Vlugt CJ; Bleijs DA; Bergmans HE
Curr Gene Ther; 2013 Dec; 13(6):395-412. PubMed ID: 24397527
[TBL] [Abstract][Full Text] [Related]
6. Biosafety of gene therapy vectors derived from herpes simplex virus type 1.
Lim F; Khalique H; Ventosa M; Baldo A
Curr Gene Ther; 2013 Dec; 13(6):478-91. PubMed ID: 24397529
[TBL] [Abstract][Full Text] [Related]
7. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
Verheust C; Goossens M; Pauwels K; Breyer D
Vaccine; 2012 Mar; 30(16):2623-32. PubMed ID: 22342706
[TBL] [Abstract][Full Text] [Related]
8. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
9. Biosafety of recombinant adeno-associated virus vectors.
Dismuke DJ; Tenenbaum L; Samulski RJ
Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
[TBL] [Abstract][Full Text] [Related]
10. Identification of potentially hazardous human gene products in GMO risk assessment.
Bergmans H; Logie C; Van Maanen K; Hermsen H; Meredyth M; Van Der Vlugt C
Environ Biosafety Res; 2008; 7(1):1-9. PubMed ID: 18384725
[TBL] [Abstract][Full Text] [Related]
11. The Genetically Modified Organism Medicinal Framework in Europe, United States, and Japan: Underlying Scientific Principles and Considerations Toward the Development of Gene Therapy and Genetically Modified Cell-Based Products.
Bachtarzi H; Farries T
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):114-128. PubMed ID: 31111736
[No Abstract] [Full Text] [Related]
12. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust.
Bamford KB; Wood S; Shaw RJ
QJM; 2005 Feb; 98(2):75-86. PubMed ID: 15655100
[TBL] [Abstract][Full Text] [Related]
13. Biosafety of non-human therapeutic viruses in clinical gene therapy.
Hoeben RC; Louz D; Koppers-Lalic D
Curr Gene Ther; 2013 Dec; 13(6):492-9. PubMed ID: 24397530
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework.
Kauffmann F; Van Damme P; Leroux-Roels G; Vandermeulen C; Berthels N; Beuneu C; Mali S
Vaccine; 2019 Sep; 37(42):6144-6153. PubMed ID: 31493949
[TBL] [Abstract][Full Text] [Related]
15. Environmental risk assessment for medicinal products containing genetically modified organisms.
Anliker B; Longhurst S; Buchholz CJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):52-7. PubMed ID: 19940966
[TBL] [Abstract][Full Text] [Related]
16. Viral-mediated gene transfer for cancer treatment.
Wilson DR
Curr Pharm Biotechnol; 2002 Jun; 3(2):151-64. PubMed ID: 12022258
[TBL] [Abstract][Full Text] [Related]
17. Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines.
Louz D; Bergmans HE; Loos BP; Hoeben RC
J Gene Med; 2005 Oct; 7(10):1263-74. PubMed ID: 15986492
[TBL] [Abstract][Full Text] [Related]
18. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.
Boeckle S; Wagner E
AAPS J; 2006; 8(4):E731-42. PubMed ID: 17285739
[TBL] [Abstract][Full Text] [Related]
19. [Gene therapy, where does it stand today].
Hacein-Bey-Abina S
J Med Liban; 2004; 52(1):32. PubMed ID: 15881699
[No Abstract] [Full Text] [Related]
20. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.
Rethwilm A
Curr Gene Ther; 2007 Aug; 7(4):261-71. PubMed ID: 17969559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
